Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

14.49
+0.35002.48%
Post-market: 14.490.00000.00%19:30 EDT
Volume:761.30K
Turnover:10.97M
Market Cap:668.35M
PE:18.34
High:14.70
Open:14.12
Low:14.05
Close:14.14
52wk High:64.23
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:0.97
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7900
EPS(LYR):1.80
ROE:16.40%
ROA:3.99%
PB:2.24
PE(LYR):8.05

Loading ...

Press Release: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Dow Jones
·
May 14

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

GlobeNewswire
·
May 14

U.S. Earnings Preview: After Market Close May 12

Dow Jones
·
May 13

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

GlobeNewswire
·
May 12

Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 12

Oddity Tech faces shareholder class action over alleged digital ad cost misstatements

Reuters
·
May 07

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 07

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

GlobeNewswire
·
May 07

Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed

Simply Wall St.
·
May 02

A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures

Simply Wall St.
·
May 01

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire
·
Apr 30

Oddity price target lowered to $14 from $18 at Jefferies

TIPRANKS
·
Apr 29

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

prnewswire
·
Apr 28

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Oddity Tech faces shareholder class action over alleged advertising cost disclosure omissions

Reuters
·
Apr 23

Radiopharm Theranostics Reports Business Update

GlobeNewswire
·
Apr 23

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

GlobeNewswire
·
Apr 21

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

TIPRANKS
·
Apr 17

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian
·
Apr 17

Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures

Reuters
·
Apr 16